Patents by Inventor Charles Eigenbrot

Charles Eigenbrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190177366
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, JR., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Publication number: 20070092940
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: September 22, 2005
    Publication date: April 26, 2007
    Applicant: Genentech, Inc.
    Inventors: Charles Eigenbrot, Jagath Junutula, Henry Lowman, Helga Raab, Richard Vandlen
  • Publication number: 20060177446
    Abstract: The present invention relates to antibodies and polypeptides useful in blocking the binding of antibodies to anti-tissue factor, decreasing the activity of the anti-tissue factor antibodies and/or neutralizing the activity of an anti-tissue factor antibody. The present invention also relates to nucleic acids encoding the antibodies and polypeptides and compositions comprising the antibodies or polypeptides or nucleic acid molecules. The present invention provides methods of treating a hypercoagulable state or an inflammatory disease using the antibodies and polypeptides of this invention and other methods of using said antibodies and polypeptides.
    Type: Application
    Filed: November 29, 2005
    Publication date: August 10, 2006
    Applicant: GENENTECH, INC.
    Inventors: Charles Eigenbrot, Yu-Ju Meng, Daniel Kirchhofer, Leonard Presta
  • Patent number: 7084109
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: August 1, 2006
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Charles Eigenbrot, Robert A. Lazarus
  • Publication number: 20060019893
    Abstract: Novel compounds are provided which modulate a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention are variants of Factor VIIa (FVIIa). Pharmaceutical compositions are also provided which comprise the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: June 23, 2005
    Publication date: January 26, 2006
    Applicant: Genentech, Inc.
    Inventors: Henry Maun, Charles Eigenbrot, Robert Lazarus
  • Publication number: 20060003931
    Abstract: The disclosure provides a crystal and crystal structure of the Hepatocyte Growth Factor Beta (HGF ?) Chain, as well as use of the crystal structure in the design, identification, and selection of modulators of HGF or Met activity.
    Type: Application
    Filed: May 6, 2005
    Publication date: January 5, 2006
    Applicant: Genentech, Inc.
    Inventors: Charles Eigenbrot, Daniel Kirchhofer, Robert Lazarus
  • Publication number: 20030119727
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Application
    Filed: July 25, 2002
    Publication date: June 26, 2003
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Charles Eigenbrot, Robert A. Lazarus